Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. 1996

M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron

UI MeSH Term Description Entries
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D014644 Genetic Variation Genotypic differences observed among individuals in a population. Genetic Diversity,Variation, Genetic,Diversity, Genetic,Diversities, Genetic,Genetic Diversities,Genetic Variations,Variations, Genetic
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D019259 Lamivudine A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. 2',3'-Dideoxy-3'-thiacytidine,2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-,3TC Lamivudine,Lamivudine, (+)-cis-,Lamivudine, (+-)-trans-,BCH-189,Epivir,GR-109714X,GR109714X,Lamivudine, (2S-cis)-Isomer,2',3' Dideoxy 3' thiacytidine,BCH 189,BCH189,GR 109714X,Lamivudine, 3TC

Related Publications

M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
February 1998, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
January 1998, Antiviral therapy,
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
January 2001, Teratology,
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
January 1999, Antiviral therapy,
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
September 1997, AIDS (London, England),
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
January 1997, Microbiology and immunology,
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
September 1997, Biochemical pharmacology,
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
January 2002, Antiviral research,
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
January 2000, Journal of acquired immune deficiency syndromes (1999),
M G Goulden, and N Cammack, and P L Hopewell, and C R Penn, and J M Cameron
May 2009, PloS one,
Copied contents to your clipboard!